AlphAIAlphAI — Financial news for AI agents
tradingview.comOCT 131 min read

HC Wainwright & Co. reiterates Buy rating on Zenas BioPharma, $44 price target

HC Wainwright & Co. maintained a Buy rating on Zenas BioPharma (ZBH) with a $44 price target, suggesting a 66.7% upside. The firm cited positive data on obexelimab's efficacy and initial vaccine sub-study results.

Original reporting
tradingview.com
Published Oct 13, 2026, 10:33 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 13, 2026, 10:44 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
HC Wainwright & Co. reiterates Buy rating on Zenas BioPharma, $44 price target — source image
Source · tradingview.com
Decision brief

The 30-second read

Med
01

Why it matters

The upgrade could attract new capital into Zenas BioPharma, lifting its share price toward the $44 target.

02

Market read

Analyst upgrade provides a fresh catalyst for a small‑cap biotech, offering a short‑term trading opportunity.

03

What to watch

Potential regulatory hurdles and competition in autoimmune therapy could temper upside.

Relevance 6/10Novelty 5/10Timing: today

Background

The note highlights positive Phase 2 data for obexelimab and a vaccine sub‑study, supporting the analyst's bullish stance.

Market effects

Sector

Positive sentiment may spill over to other biotech stocks as analysts highlight therapeutic potential.

Regional

Limited to US biotech sector; no broader regional effect.

Global

Minimal global impact beyond niche biotech investors.

Counterpoint

What could challenge this read

The price target may be overly optimistic given early-stage data; investors could wait for more mature trial results.

Key entities

  • analyst
    HC Wainwright & Co.

    Equity research firm issuing the Buy rating and price target.

  • company
    Zenas BioPharma

    Biotech firm developing obexelimab for autoimmune diseases.

Read at source← All news

Related articles

OCT 13
$ZBIOMedAI 8/10

Zenas BioPharma Announces the Presentation of New Obexelimab Data in IgG4-Related Disease at the 6th International Symposium on IgG4-Related Disease

Zenas BioPharma, Inc. (ZBIO) filed an SEC Form 8-K — Regulation FD Disclosure. Exhibit 99.1 Zenas BioPharma Announces the Presentation of New Obexelimab Data in IgG4-Related Disease at the 6th International Symposium on IgG4-Related Disease | Source: Zenas BioPharma Share – Phase 3 INDIGO open-label extension findings demonstrated sustained clinical activit

SEC EDGAR 8-K2 min
OCT 12
$ZBIOMedAI 8/10

COVID vaccination produced immune responses in all 4 participants during a planned treatment break

Zenas BioPharma presented Phase 3 data on obexelimab for IgG4-RD, showing sustained flare protection, reduced steroid toxicity, and vaccine responses during treatment breaks. The study included 4 participants who developed COVID-19 immunity. Zenas (Nasdaq: ZBIO) is a clinical-stage biopharmaceutical company focused on autoimmune and inflammatory diseases.

stocktitan.net2 min
AUG 13
$ZBIOMed

Zenas BioPharma Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Zenas BioPharma, Inc. (ZBIO) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Zenas BioPharma Reports Second Quarter 2026 Financial Results and Provides Corporate Update - Obexelimab BLA submission for the treatment of IgG4-RD accepted by FDA; PDUFA target action date of May 27, 2027 - - New study data confirm bioequivalence of obexelimab sing

SEC EDGAR 8-K6 min